While Beta Bionics Inc has underperformed by -37.04%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BBNX fell by -33.90%, with highs and lows ranging from $32.71 to $8.89, whereas the simple moving average jumped by 2.36% in the last 200 days.
On January 09, 2026, BofA Securities Downgraded Beta Bionics Inc (NASDAQ: BBNX) to Neutral. Goldman also Upgraded BBNX shares as ‘Buy’, setting a target price of $26 on the company’s shares in a report dated October 01, 2025. Truist Initiated an Buy rating on June 16, 2025, and assigned a price target of $26. Lake Street initiated its ‘Buy’ rating for BBNX, as published in its report on June 12, 2025. Wolfe Research’s report from May 30, 2025 suggests a price prediction of $20 for BBNX shares, giving the stock a ‘Outperform’ rating. Goldman also rated the stock as ‘Neutral’.
Analysis of Beta Bionics Inc (BBNX)
Further, the quarter-over-quarter increase in sales is 63.14%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Beta Bionics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -47.52% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 9.83, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 774.55K can be a very valuable indicator of volatility for BBNX stock. On a monthly basis, the volatility of the stock is set at 6.22%, whereas on a weekly basis, it is put at 8.81%, with a loss of -31.15% over the past seven days. Furthermore, long-term investors anticipate a median target price of $32.10, showing growth from the present price of $20.14, which can serve as yet another indication of whether BBNX is worth investing in or should be passed over.
How Do You Analyze Beta Bionics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 24.07%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 95.27% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
